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A B S T R A C T
In total, 844 strains of Gram-positive cocci were collected from six university hospitals in France between
September 1999 and January 2000. MICs of linezolid were determined: (i) for all strains by agar dilution
(method A); (ii) by broth microdilution (method B) for staphylococci and enterococci; (iii) by Etest
(method E) for b-haemolytic streptococci and Streptococcus pneumoniae. Susceptibility to other antibiotics
was determined by the disk diffusion method. MIC50 and MIC90 values were identical (2 mg ⁄L) for
methicillin-susceptible Staphylococcus aureus (n ¼ 179) by methods A and B. Linezolid was active against
methicillin-resistant S. aureus (n ¼ 117), with an MIC90 of 2 mg ⁄L (methods A and B), but with a lower
MIC50 of 1 mg ⁄L by method A. Of the 200 coagulase-negative staphylococci, 56.5% were methicillin-
resistant and 43.5% were methicillin-susceptible. Linezolid had similar in-vitro activity by methods A
and B (MIC50 and MIC90 values of 1–2 mg ⁄L), irrespective of methicillin susceptibility. The MIC90 of
linezolid for all enterococci (150 Enterococcus faecalis and 50 Enterococcus faecium) was 2 mg ⁄L by both
methods. MICs of linezolid for b-haemolytic streptococci had a narrow range of 0.5–2 mg ⁄L (method A)
and 0.125–2 mg ⁄L (method E). Pneumococci (n ¼ 118), including 67 penicillin G-intermediate and -
resistant strains, were all inhibited by linezolid 2 mg ⁄L (MIC90 of 2 mg ⁄L by methods A and E). No strain
had an MIC of > 2 mg ⁄L by agar dilution or Etest, or of > 4 mg ⁄L by broth microdilution. Overall, the
study confirmed the good in-vitro activity of linezolid and the very narrow range of MICs for Gram-
positive cocci susceptible or resistant to other antibiotics, irrespective of the method used.
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Linezolid is the first member of a new class of
synthetic antibacterial agents known as oxazolid-
inones, which act by inhibiting initiation of protein
synthesis [1,2]. The targets of oxazolidinones
appear not to be recognised by other antibacterial
agents, since no cross-resistance has been found in
strains resistant to other antibiotics [3,4]. The
in-vitro and in-vivo spectrum of activity of linezo-
lid is primarily against Gram-positive cocci, inclu-
ding methicillin-resistant Staphylococcus aureus
(MRSA), coagulase-negative staphylococci (CNS),
and enterococci, especially vancomycin- and
ampicillin-resistant strains and penicillin-suscept-
ible and -resistant Streptococcus pneumoniae isolates
[5–7]. Linezolid demonstrates good in-vitro
activity against Gram-positive anaerobes (MICs
of 1–2 mg ⁄L) and some species of Gram-negative
bacilli, including Bacteroides spp., Fusobacterium
nucleatum and Prevotella spp. [8–10]. The aims of
this study were: (i) to assess the activity of
linezolid against a large number of recent clinical
isolates collected in six French university hospi-
tals; and (ii) to evaluate the in-vitro activity of
linezolid by different methods.
M A T E R I A L S A N D M E T H O D S
Study design
Six French teaching hospital laboratories were enrolled in the
study. Each participating centre tested c.150 Gram-positive
clinical isolates according to a standardised protocol. The
isolates comprised (maximum number): methicillin-suscept-
ible S. aureus (MSSA) (30), MRSA (20), methicillin-susceptible
CNS (15), methicillin-resistant CNS (20), Enterococcus faecium
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(30), Enterococcus faecalis (10), other Enterococcus spp. (40),
Strep. pneumoniae (20), and other Streptococcus spp. (viridans
group or b-haemolytic streptococci) (5). Non-repetitive iso-
lates were collected between September 1999 and January
2000.
The strains were isolated from the following body sites:
blood (only isolates considered as clinically significant by local
laboratory criteria), cerebrospinal fluid, skin and skin struc-
tures (i.e., post-surgical wound, lower extremity infection site,
traumatic wound, cellulitis, abscess), bone and joint, intra-
abdominal (i.e., peritonitis, intra-abdominal abscess), lower
respiratory tract (i.e., tracheal aspirate, bronchoalveolar lavage,
bronchial brush, pleural fluid, sputum), and upper respiratory
tract (i.e., sinus, middle ear).
Susceptibility testing methods
Several different methods were used for antibiotic suscepti-
bility testing.
MIC determination
MICs of linezolid were determined by agar dilution (method
A) using Mueller-Hinton number 2 medium (bioMe´rieux; La
Balme les Grottes, France) for staphylococci and enterococci,
supplemented with defibrinated sheep blood 5% v ⁄v for
Strep. pneumoniae and groups A, B, C and G streptococci.
Isolates were incubated at 37 C in ambient atmosphere for
staphylococci and enterococci and in CO2 5% v ⁄v for other
species. The inocula comprised 104 CFU ⁄ spot. In addition,
MICs for staphylococci and enterococci were determined by
broth microdilution in a cation-adjusted Mueller-Hinton
broth incubated at 35 C for 18–24 h in ambient atmosphere
(method B); MICs for Strep. pneumoniae and groups A, B, C
and G streptococci were obtained by Etest (AB Biodisk,
Solna, Sweden) (method E) on Mueller-Hinton number 2
agar with sheep blood 5% v ⁄v and an inoculum of c.
108 CFU ⁄mL.
Disk diffusion
Antibiotic susceptibility testing by agar plate disk diffusion
was performed in each participating laboratory. The antimi-
crobial agents tested varied according to the species, but
included b-lactams (penicillin, methicillin), macrolides (eryth-
romycin, lincomycin, pristinamycin), a fluoroquinolone (pefl-
oxacin), glycopeptides (vancomycin, teicoplanin) and an
aminoglycoside (gentamicin). Zone diameters were measured
after incubation for 18–24 h. Isolates were classified as sus-
ceptible, intermediate or resistant according to the guidelines
of the Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de
Microbiologie (CA-SFM) [11].
Quality assurance
Internal quality control was carried out with S. aureus strains
ATCC 25923 and ATCC 29213, Strep. pneumoniae strain ATCC
49619, and E. faecalis strain ATCC 29212. Each strain was tested
ten times during the study by the MIC and disk-diffusion
methods in each laboratory.
R E S U L T S
In total, 844 clinical strains (Table 1) were collec-
ted and tested as consecutive isolates.
Among the 296 S. aureus isolates, 117 (39.5%)
were methicillin-resistant (MRSA). Most MRSA
isolates were also resistant to erythromycin
(80.3%) and lincomycin (74.4%), indicating that
resistance to macrolides was mainly of the consti-
tutive MLSB phenotype. Resistance rates to pefl-
oxacin were very high (93.2%), and the resistance
rate to gentamicin reached 34.2% among
MRSA strains. MSSA were resistant to erythro-
mycin less frequently (20.7%) and lincomycin
(8.5%), and resistance to gentamicin and pefloxa-
cin remained rare (0.6% and 4.5%, respectively).
Linezolid MIC ranges were similar for MSSA
and MRSA, with most MIC values between 1
and 2 mg ⁄L (Fig. 1). MIC50 and MIC90 values of
linezolid, measured by methods A and B, were
similar for MSSA (2 mg ⁄L). For MRSA, the
linezolid MIC50 was slightly lower (1 mg ⁄L) by
method A. The MIC was 4 mg ⁄L by method B
for six S. aureus isolates (four MSSA and two
MRSA).
Of the 200 CNS isolates, 56.5%were methicillin-
resistant and 43.5% were methicillin-susceptible.
Of the methicillin-resistant CNS, 61% were also
resistant to erythromycin, 35.4% to lincomycin,
57.5% to gentamicin and 79.6% to pefloxacin. One
strain was resistant to teicoplanin, but all strains
were susceptible to vancomycin. Only 33.3% and
4.6% of methicillin-susceptible CNS were resist-
ant, respectively, to erythromycin and lincomycin.
One strain was gentamicin-resistant and only four
Table 1. Distribution of strains by
culture source
S. aureus CNS E. faecalis E. faecium Strep. pneumoniae Streptococci Total
Blood 76 87 47 13 30 10 263
Intra-abdominal 4 11 34 26 0 1 76
Skin and skin structure 50 9 23 2 0 8 92
Upper respiratory 17 2 1 0 14 2 36
Lower respiratory 79 9 3 2 58 1 152
Cerebrospinal fluid 3 10 0 0 3 0 16
Bone and joint 18 15 3 0 0 2 38
Others 49 57 39 7 13 6 171
Total 296 200 150 50 118 30 844
CNS, coagulase-negative staphyloccoci.
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strains were resistant to pefloxacin. The linezolid
MIC distributions are shown in Fig. 2. All isolates
were susceptible to linezolid, with MICs of 0.125–
2 mg ⁄L by method A, and 0.25–4 mg ⁄L by
method B. The MIC50 and MIC90 values were
similar for methicillin-resistant and methicillin-
susceptible CNS (1 and 2 mg ⁄L, respectively) by
methods A and B.
Of the 200 enterococci tested, E. faecalis accoun-
ted for 75% and E. faecium for 25%. Only 34.6% of
E. faecalis and 18% of E. faecium isolates remained
susceptible to erythromycin. Approximately 10%
of the two species showed high-level resistance to
gentamicin. Ampicillin resistance rates reached
56% for E. faecium. All the enterococci were
susceptible to glycopeptides. The linezolid MIC
ranges for enterococci, by methods A and B, are
shown in Fig. 3. Linezolid MIC50 and MIC90
values for E. faecalis and E. faecium were both
2 mg ⁄L by method A, but the linezolid MIC90 for
E. faecalis was one dilution higher (4 mg ⁄L) by
method B.
Of 118 clinical isolates of Strep. pneumoniae,
45.8% and 11%, respectively, were either inter-
mediate or resistant to penicillin G (MIC of
> 1 mg ⁄L). Two strains were resistant to cefotax-
ime (MIC of > 2 mg ⁄L) [11], while resistance rates
to erythromycin and lincomycin reached 57.6%.
All the strains were susceptible to linezolid, with
MICs of 0.25–2 mg ⁄L (Fig. 4). MIC50 and MIC90
values were 1 and 2 mg ⁄L, respectively, by
method A, but the MIC50 appeared lower
(0.38 mg ⁄L) when measured by Etest.
The 30 b-haemolytic streptococci included four
erythromycin-resistant and three lincomycin-
resistant strains, thereby indicating a low
prevalence of macrolide resistance. All 30 strains
were susceptible to cefotaxime and glycopeptides.
Linezolid was active against all isolates with
MICs of 0.5–2 mg ⁄L by method A, and 0.125–
2 mg ⁄L by method E. The distribution of linezo-
lid MICs for b-haemolytic streptococci groups A,
B, C and G is shown in Fig. 5. The MIC90 value
was similar by the two methods (2 mg ⁄L), while
the MIC50 value was one dilution lower by
method E (0.5 mg ⁄L) compared to method A
(1 mg ⁄L).
D I S C U S S I O N
Linezolid, an oxazolidinone, is being developed
to treat infections caused by Gram-positive
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Fig. 1. Distribution of MICs of linezolid against S. aureus
(n ¼ 296) by agar dilution (method A) and broth microdi-
lution (method B).
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Fig. 2. Distribution of MICs of linezolid against coagulase
negative staphylococci (n ¼ 200) by agar dilution (method
A) and broth microdilution (method B).
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bacteria, including those resistant to the antibiot-
ics currently available. In the present study,
linezolid had the same activity against MSSA,
MRSA and CNS. These results are in agreement
with previous studies [12–14]. Linezolid is active
against glycopeptide non-susceptible staphylo-
cocci [15], although only one teicoplanin-resistant
strain of CNS (susceptible to linezolid) was
isolated in this study.
Linezolid had potent activity against entero-
cocci, irrespective of vancomycin and ampicillin
susceptibilities. MIC90 values were similar for
vancomycin-susceptible and vancomycin-resist-
ant enterococci [16]. Linezolid was also very
active against Strep. pneumoniae, regardless of
penicillin or erythromycin resistance, with MICs
always £ 2 mg ⁄L. Other studies have shown
similar findings [17,18]. However, in the present
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Fig. 3. Distribution of MICs of line-
zolid against enterococci by agar
dilution (method A) and broth micro-
dilution (method B).
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Fig. 4. Distribution of MICs of linezolid against S. pneu-
moniae (n ¼ 118) by agar dilution (method A) and Etest
(method E).
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Fig. 5. Distribution of MICs of linezolid against other
streptococci (n ¼ 30) by agar dilution (method A) and
Etest (method E).
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study, the MICs appeared lower for Strep. pneu-
moniae when measured by Etest (MIC50 of
0.38 mg ⁄L). Linezolid was also very active against
erythromycin-resistant b-haemolytic streptococci
[19,20].
For each group of bacteria included in this
study, the linezolid MICs never exceeded 4 mg ⁄L,
and linezolid was equally active against strains
that were multiply-resistant to other antibiotics.
These results suggest that linezolid is a valuable
antimicrobial agent for the treatment of serious
infections caused by Gram-positive cocci.
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